FDA optimistic about Pfizer drugs to treat breast cancer palbociclib
Pfizer, the FDA new drug developed to treat breast cancer palbociclib (PD-0332991) high hopes. The FDA reviewed the interim results of the drug after that this may be a breakthrough cancer drug.
Palbociclib as the most important one three Pfizer study drug is an oral cyclin-dependent kinase inhibitor 4,6.
Last year, Pfizer has five drugs received FDA clearance to market, while the company also carried out on the existing research institutions drastically streamlining and cancer drug development as the company's main research directions.
FDA optimistic about Pfizer drugs to treat breast cancer palbociclib
ReplyDeletePfizer, the FDA new drug developed to treat breast cancer palbociclib (PD-0332991) high hopes. The FDA reviewed the interim results of the drug after that this may be a breakthrough cancer drug.
Palbociclib as the most important one three Pfizer study drug is an oral cyclin-dependent kinase inhibitor 4,6.
Last year, Pfizer has five drugs received FDA clearance to market, while the company also carried out on the existing research institutions drastically streamlining and cancer drug development as the company's main research directions.
Medchemexpress Can provide the above product,its website:www.medchemexpress.com
ABT-737
Nutlin-3a chiral
p53 and MDM2 proteins-interaction-inhibitor
Serdemetan
Nutlin-3b
Nutlin-3
p53 and MDM2 proteins-interaction-inhibitor chiral
p53 and MDM2 proteins-interaction-inhibitor (racemic)
YM-155
Pomalidomide